18 related articles for article (PubMed ID: 24684541)
1. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
Front Immunol; 2020; 11():594556. PubMed ID: 33312177
[TBL] [Abstract][Full Text] [Related]
2. Molecular Interactions Between Innate and Adaptive Immune Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.
Haseeb M; Anwar MA; Choi S
Front Immunol; 2018; 9():2720. PubMed ID: 30542344
[TBL] [Abstract][Full Text] [Related]
3. Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.
Cattaneo F; Patrussi L; Capitani N; Frezzato F; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Oncotarget; 2016 Aug; 7(35):57086-57098. PubMed ID: 27494881
[TBL] [Abstract][Full Text] [Related]
4. Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia.
Mohr A; Renaudineau Y; Bagacean C; Pers JO; Jamin C; Bordron A
Oncoimmunology; 2016 May; 5(5):e1132977. PubMed ID: 27467951
[TBL] [Abstract][Full Text] [Related]
5. Tumour-loaded α-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia produce a superior NK-, NKT- and CD8+ T cell-attracting chemokine profile.
Gustafsson K; Junevik K; Werlenius O; Holmgren S; Karlsson-Parra A; Andersson PO
Scand J Immunol; 2011 Sep; 74(3):318-326. PubMed ID: 21595737
[TBL] [Abstract][Full Text] [Related]
6. Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy.
Hansen M; Hjortø GM; Donia M; Met Ö; Larsen NB; Andersen MH; thor Straten P; Svane IM
Vaccine; 2013 Jan; 31(4):639-46. PubMed ID: 23200882
[TBL] [Abstract][Full Text] [Related]
7. Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70.
Pen JJ; De Keersmaecker B; Maenhout SK; Van Nuffel AM; Heirman C; Corthals J; Escors D; Bonehill A; Thielemans K; Breckpot K; Aerts JL
J Immunol; 2013 Aug; 191(4):1976-83. PubMed ID: 23842750
[TBL] [Abstract][Full Text] [Related]
8. Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells.
Hwang EC; Lim MS; Im CM; Kwon DD; Lee HJ; Nguyen-Pham TN; Lee YK; Lee JJ
Scand J Immunol; 2013 Feb; 77(2):117-24. PubMed ID: 23126536
[TBL] [Abstract][Full Text] [Related]
9. CD70 is selectively expressed on Th1 but not on Th2 cells and is required for Th1-type immune responses.
Kawamura T; Ogawa Y; Shimozato O; Ando T; Nakao A; Kobata T; Okumura K; Yagita H; Shimada S
J Invest Dermatol; 2011 Jun; 131(6):1252-61. PubMed ID: 21490618
[TBL] [Abstract][Full Text] [Related]
10. High functional CD70 expression on α-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia.
Junevik K; Werlenius O; Fogelstrand L; Karlsson-Parra A; Andersson PO
Scand J Immunol; 2014 Jun; 79(6):415-22. PubMed ID: 24684541
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
